Marie-Hélène Lafeuille

Education

M.A. and B.A., economics, Université de Sherbrooke

Summary of Experience

Ms. Lafeuille specializes in health economics and outcomes research. She has conducted a wide range of analyses for the investigation of, among other topics, clinical efficacy, safety profile, cost of illness, resource utilization patterns, treatment patterns, and cost-effectiveness in a broad range of disease areas, including oncology, hematology, schizophrenia, asthma, diabetes mellitus, epilepsy, chronic kidney disease, and cardiovascular diseases. Ms. Lafeuille has extensive experience performing retrospective insurance claims database analyses, retrospective electronic medical record and chart review studies, clinical trial data analyses, and systematic literature reviews (including meta-analyses). Her research has been presented at numerous international clinical conferences, and she has published on various health economic topics, including treatment patterns, direct and indirect resource utilization and medical costs, and drug cost-effectiveness, in several peer-reviewed journals, including Neurology, Hypertension, Cancer, and Menopause. Ms. Lafeuille is a member of the International Society of Pharmacoeconomics and Outcomes Research.

En Français

Selected Publishing

• Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting

  Endocrine Practice. 03 2018;24(3):273-287
  2018

  Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P

• Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting

  Current Medical Research and Opinion. Mar 27 2018:1-9
  2018

  Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P

• Economic burden of treatment failure in chronic lymphocytic leukemia patients

  Current Medical Research and Opinion. 24 Apr 2018:1-8
  2018

  Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M

• Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin

  Current Medical Research and Opinion. 05 Mar 2018:1-17
  2018

  Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA

  Health Care
• Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting

  Current Medical Research and Opinion. Oct 2017;33(10):1763-1772
  2017

  Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N 

  Health Care
• Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program

  Current Medical Research and Opinion. Apr 2017;33(4):713-721
  2017

  Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ

  Health Care
• Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

  BMC Endocrine Disorders. Jun 08 2017;17(1):32
  2017

  Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS

  Health Care
• Burden of systemic glucocorticoid-related complications in severe asthma(1)

  Current Medical Research and Opinion. Jan 2017;33(1):57-65
  2017

  Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA

  Health Care
• Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics

  Clinical Therapeutics. Oct 2017;39(10):1972-1985 e1972
  2017

  Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K

  Health Care
• Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology

  Leukemia and Lymphoma. Aug 2017;58(8):1968-1972
  2017

  Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A

• Burden of systemic glucocorticoid-related complications in severe asthma

  Current Medical Research and Opinion, 2016 Oct 14:1-29
  2016

  Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA. 

  Health Care
• Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics

  Current Medical Research and Opinion, 2016 04; 32(4): 759-769. e-pub ahead of print 2016/01/12
  2016

  Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P. 

  Health Care, Insurance
• Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.

  Current Medical Research and Opinion, Opin 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27
  2016

  Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.

  Health Care
• Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus

  American Journal of Managed Care, Volume 20, Number 1, Supplement - January 2014
  2014

  Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M

  Health Care
• Incremental direct and indirect costs of untreated vasomotor symptoms

  Menopause, August 25, 2014
  2014

  Sarrel P, Portman D, Lefebvre P, Lafeuille M, Grittner A, Fortier J, Gravel J, Duh MS, Aupperle P

  Health Care
• Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia

  Leuk Lymphoma. 2011 Nov 23
  2011

  Lafeuille M, Vekeman F, Wang S, Kerrigan M, Menditto L, Duh MS

  Health Care
• Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings

  J Med Econ. 2011 Dec 14.
  2011

  Lafeuille M, Bailey R, Vekeman F, Scott McKenzie R, Lefebvre P 

  Health Care
• Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain Medications

  Pain Med. 2010 Nov;11(11):1718-25
  2010

  Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P

  Epidemiology & Biostatistics, Health Care
• Generic antiepileptic drugs and associated medical resource utilization in the United States

  Neurology 2010 74: 1566-1574
  2010

  Labiner D, Paradis P, Manjunath R, Duh MS, Lafeuille M, Latremouille-Viau D, Lefebvre P, Helmers S

  Epidemiology & Biostatistics, Health Care
• Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

  Curr Med Res Opin. 2009; 25(7):1793-1805
  2009

  Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille M, Lefebvre P, Gaudig M, Duh MS

  Health Care

News

• April 16, 2018

  AMCP’s Managed Care & Specialty Pharmacy Annual Meeting to Feature New Outcomes Research from Analysis Group

  Health Care
• April 04, 2018

  Analysis Group Welcomes New Affiliates and Consultants, and Announces Recent Promotions

• September 19, 2016

  Analysis Group Researchers Present at Major Health Care Conference

  Health Care,